GSK Cuts Price Of Cervarix Vaccine By 30% In Singapore
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - GlaxoSmithKline has announced the company recently reduced the price of its cervical cancer vaccine Cervarix by 30 percent in Singapore
You may also be interested in...
GSK Sees Enduring Pricing Pressure Unlikely, Novo Projects Lower Growth In China, Lilly Bolsters Diabetes Presence In India: Emerging Markets Round Up (Part 1)
In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets. In Q3, earnings in emerging markets were slightly down for GlaxoSmithKline PLC, Novo Nordisk A/S, and Eli Lilly & Co, mostly due to increased pricing pressure as well as increased competition in the diabetes market, with local players rapidly gaining market share..
GSK Sees Enduring Pricing Pressure Unlikely, Novo Projects Lower Growth In China, Lilly Bolsters Diabetes Presence In India: Emerging Markets Round Up (Part 1)
In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets. In Q3, earnings in emerging markets were slightly down for GlaxoSmithKline PLC, Novo Nordisk A/S, and Eli Lilly & Co, mostly due to increased pricing pressure as well as increased competition in the diabetes market, with local players rapidly gaining market share..
Sanofi To Cut Drug Prices In South East Asia In Experiment Aimed At Creating A Sustainable Model Of Access
SHANGHAI - Sanofi-Aventis hopes to widen the availability of its medicines in less developed nations by slashing the price of some drugs in Southeast Asia, in a move that could be modeled after a similar program launched by GlaxoSmithKline one year ago